Accepted Manuscript

Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with *in vivo* activity

Kenneth Meyers, Derek A. Cogan, Jennifer Burke, Raquel Arenas, Michael Balestra, Nicholas F. Brown, Matthew A. Cerny, Holly E. Clifford, Federico Colombo, Lee Fader, Kosea S. Frederick, Xin Guo, Keith R. Hornberger, Stanley Kugler, John Lord, Daniel R. Marshall, Neil Moss, Jeremy R. Richman, Jennifer Schmenk, Steven M. Weldon, Maolin Yu, Michael Zhang, Zhidong Chen



PII: DOI: Reference:	S0960-894X(17)31175-7 https://doi.org/10.1016/j.bmcl.2017.12.015 BMCL 25471
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date: Revised Date:	28 March 2017 6 December 2017 7 December 2017
Accepted Date:	/ December 201 /

Please cite this article as: Meyers, K., Cogan, D.A., Burke, J., Arenas, R., Balestra, M., Brown, N.F., Cerny, M.A., Clifford, H.E., Colombo, F., Fader, L., Frederick, K.S., Guo, X., Hornberger, K.R., Kugler, S., Lord, J., Marshall, D.R., Moss, N., Richman, J.R., Schmenk, J., Weldon, S.M., Yu, M., Zhang, M., Chen, Z., Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with *in vivo* activity, *Bioorganic & Medicinal Chemistry Letters* (2017), doi: https://doi.org/10.1016/j.bmcl.2017.12.015

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.